Influenza Diagnostics Market Challenges, Trend Analytics and Forecast to 2023
An New Research on “Influenza Diagnostics Market 2023” has been recorded
Market Overview:
Influenza as an illness can cause severe complications and mess up anybody's medical history. Influenza is of various types and with a variety of deadly symptoms. Hence, early diagnosis of influenza can reduce the chances of further complications. Therefore, with World Health Organization (WHO) confirming about 600 million Influenza cases worldwide, the services offering accurate Influenza diagnosis are going to be in-demand always and become a part of a huge market in the medical sector.
Market Research Future (MRFR) has published a report about the global Influenza Diagnostics Market. This report expects 5.8% CAGRduring the forecast period between 2017 and 2023. In terms of cash, this market is expected to grow with US $ 700.7 mn by 2023. This report analyzes the market, potential for growth during the forecast period, market sizes around the world, key players in the market, product launches and latest research and development (R&D). The global influenza diagnostics market is on the basis of types, tests,and region.The segmentation of types comprises of type A flu, type B flu, type C flu. The three forms of type A are bird flu, seasonal flu, andSwine flu. On the basis of direct fluorescent antibody (DFA) tests, molecular tests, nucleic acid sequence-based amplification (NASBA) tests, rapid influenza detection tests (RIDT), serological assays, simple amplification-based assays (SAMBA) and loop-mediated isothermal amplification-based assays (LAMP). Serological assays are segmented into primary serological tests, secondary serological tests, and tertiary serological tests. Primary serological tests cover enzyme-linkedimmunosorbent assay (ELISA), immunofluorescent antibody technique (IFAT) and radioimmunoassay (RIA). Secondary Serological tests include agglutination tests, complement fixation tests (CFT), precipitation tests, serum neutralization tests (SNT) and toxin-antitoxin test.
The regional segmentation of the global influenza diagnostics market is into the Americas (North America & South America), Europe, Asia Pacific, and Middle East & Africa (MEA). North America is believed to be the largest market for global influenza diagnostics due to advanced healthcare facilities andthe increasing presence of major market players in this region. Compared to North America, South America is a moderately smaller market,but that is not due to lack of demand but due to the lack of awareness, lack of advanced technology and lesser budgets for healthcare. In North America, the largest markets are Canada and the United States of America (USA). After North America, Europe is the largest market for influenza diagnostics. Here due to reasons same as North America, Western Europe stands with the lion's share in Europe market, compared to Eastern Europe. In Western Europe, the biggest markets are France, Germany, Italy, Spain and the United Kingdom (UK), followed by the rest of Europe. During the forecast period, Asia Pacific region is expected to experience large-scale growth of influenza diagnostics market with China, India, Japan and South Korea emerging as major markets. Remarkable growth is also expected in remaining countries of Asia Pacific region. However, compared to the Asia Pacific, MEA is expected to have limited growth, with Egypt, Saudi Arabia and the United Arab Emirates (UAE) emerging as the best bets for Influenza Diagnostics Market investors.The low market in the MEA region is primarily due to the lack of technology and education.
Key Players
The key players in global influenza diagnostics market include Alere (USA), BD (USA), Becton Dickinson (USA), BioMérieux SA (France), Cepheid (USA), Hardy Diagnostics(USA), LifeSign LLC.(USA), Meridian Bioscience, Inc.(USA), Quidel Corporation (USA), Roche Molecular Systems Inc.(Switzerland), and Sekisui Diagnostics (USA).
Latest Industry News
· Medical technology company Becton Dickinson (BD), currently a key player in global influenza diagnostics market, has formally opened a new research facility at Plassey Technological Park in Limerick. This business expansion has created 85 new jobs at its Irish operations. Currently, BD employs more than 1,300 employees in Ireland across Drogheda, Dun Laoghaire and its two sites in Limerick.
US-based leading molecular diagnostics company, Cepheid Inc, a key player in global influenza diagnostics market, has unveiled its newest configuration in the GeneXpert family of systems, the GeneXpert Edge. An owned subsidiary of Danaher, Cepheid Inc, also announced its ‘Make in India’ initiative regarding which they have plans to establish their manufacturing footprint in the country for Xpert MTB/RIF test cartridges which run on the GeneXpert System. In the last two years, more than 1,200 Cepheid’s GeneXpert Systems have been installed at various revised national tuberculosis control program (RNTCP) sites in India. Last year, more than 2.5 million cartridges were supplied at various centers of Central TB Division (CTD). The India launch of GeneXpert Edge is expected later this year.
Access Full Report Details @ https://www.marketresearchfuture.com/reports/influenza-diagnostics-market-3142